Madrigal Pharmaceuticals Stock Probability of Future Stock Price Finishing Over 347.45

MDGL Stock  USD 312.00  1.13  0.36%   
Madrigal Pharmaceuticals' future price is the expected price of Madrigal Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Madrigal Pharmaceuticals performance during a given time horizon utilizing its historical volatility. Check out Madrigal Pharmaceuticals Backtesting, Madrigal Pharmaceuticals Valuation, Madrigal Pharmaceuticals Correlation, Madrigal Pharmaceuticals Hype Analysis, Madrigal Pharmaceuticals Volatility, Madrigal Pharmaceuticals History as well as Madrigal Pharmaceuticals Performance.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.
  
At this time, Madrigal Pharmaceuticals' Price To Sales Ratio is quite stable compared to the past year. Price Book Value Ratio is expected to rise to 11.20 this year, although the value of Price Earnings To Growth Ratio is projected to rise to (0.76). Please specify Madrigal Pharmaceuticals' target price for which you would like Madrigal Pharmaceuticals odds to be computed.

Madrigal Pharmaceuticals Target Price Odds to finish over 347.45

The tendency of Madrigal Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 347.45  or more in 90 days
 312.00 90 days 347.45 
about 8.86
Based on a normal probability distribution, the odds of Madrigal Pharmaceuticals to move over $ 347.45  or more in 90 days from now is about 8.86 (This Madrigal Pharmaceuticals probability density function shows the probability of Madrigal Stock to fall within a particular range of prices over 90 days) . Probability of Madrigal Pharmaceuticals price to stay between its current price of $ 312.00  and $ 347.45  at the end of the 90-day period is about 15.28 .
Given the investment horizon of 90 days Madrigal Pharmaceuticals has a beta of 0.63. This indicates as returns on the market go up, Madrigal Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Madrigal Pharmaceuticals will be expected to be much smaller as well. Additionally Madrigal Pharmaceuticals has an alpha of 0.5517, implying that it can generate a 0.55 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Madrigal Pharmaceuticals Price Density   
       Price  

Predictive Modules for Madrigal Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Madrigal Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
280.80320.87325.42
Details
Intrinsic
Valuation
LowRealHigh
280.80334.68339.23
Details
16 Analysts
Consensus
LowTargetHigh
289.61318.25353.26
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-6.13-5.91-5.74
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Madrigal Pharmaceuticals. Your research has to be compared to or analyzed against Madrigal Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Madrigal Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Madrigal Pharmaceuticals is not an exception. The market had few large corrections towards the Madrigal Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Madrigal Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Madrigal Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.55
β
Beta against Dow Jones0.63
σ
Overall volatility
54.74
Ir
Information ratio 0.12

Madrigal Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Madrigal Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Madrigal Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Madrigal Pharmaceuticals appears to be risky and price may revert if volatility continues
Net Loss for the year was (373.63 M) with profit before overhead, payroll, taxes, and interest of 0.
Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (324.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38.
Madrigal Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 91.0% of the company shares are owned by institutional investors
Latest headline from thelincolnianonline.com: Geode Capital Management LLC Boosts Stock Position in Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Madrigal Stock often depends not only on the future outlook of the current and potential Madrigal Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Madrigal Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding18.7 M
Cash And Short Term Investments634.1 M

Madrigal Pharmaceuticals Technical Analysis

Madrigal Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Madrigal Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Madrigal Pharmaceuticals. In general, you should focus on analyzing Madrigal Stock price patterns and their correlations with different microeconomic environments and drivers.

Madrigal Pharmaceuticals Predictive Forecast Models

Madrigal Pharmaceuticals' time-series forecasting models is one of many Madrigal Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Madrigal Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Madrigal Pharmaceuticals

Checking the ongoing alerts about Madrigal Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Madrigal Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Madrigal Pharmaceuticals appears to be risky and price may revert if volatility continues
Net Loss for the year was (373.63 M) with profit before overhead, payroll, taxes, and interest of 0.
Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (324.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38.
Madrigal Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 91.0% of the company shares are owned by institutional investors
Latest headline from thelincolnianonline.com: Geode Capital Management LLC Boosts Stock Position in Madrigal Pharmaceuticals, Inc.
When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(25.03)
Revenue Per Share
3.705
Return On Assets
(0.52)
Return On Equity
(1.30)
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.